{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:56:59Z","timestamp":1781283419715,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.humimm.2026.111763","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:14:25Z","timestamp":1779855265000},"page":"111763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced socs2 expression and elevated IL-4\/IL-23 levels in multiple sclerosis patients: Implications for immune dysregulation"],"prefix":"10.1016","volume":"87","author":[{"given":"Virginia","family":"Sede\u00f1o Monge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Santos L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bautista Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora Hilda","family":"Rosas Murrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Hern\u00e1ndez Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"Gonz\u00e1lez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annia","family":"Rodr\u00edguez Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Madrazo Cabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Mar\u00eda","family":"Ben\u00edtez Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s Manuel","family":"Gallardo P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10422","key":"10.1016\/j.humimm.2026.111763_b0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.humimm.2026.111763_b0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1756285613488434","article-title":"Sex and gender issues in multiple sclerosis","volume":"6","author":"Harbo","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11940-019-0544-7","article-title":"Sleep Abnormalities in Multiple Sclerosis","volume":"21","author":"Sakkas","year":"2019","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"8","key":"10.1016\/j.humimm.2026.111763_b0020","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.humimm.2026.111763_b0025","doi-asserted-by":"crossref","unstructured":"Walton, C., et al., Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler, 2020. 26(14): p. 1816-1821.","DOI":"10.1177\/1352458520970841"},{"issue":"4","key":"10.1016\/j.humimm.2026.111763_b0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1212\/CON.0000000000001170","article-title":"Treatment of Multiple Sclerosis","volume":"28","author":"Cross","year":"2022","journal-title":"Continuum (minneap Minn)"},{"issue":"15","key":"10.1016\/j.humimm.2026.111763_b0035","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s40265-023-01942-0","article-title":"Escalation Versus Induction\/High-Efficacy Treatment strategies for Relapsing Multiple Sclerosis: which is best for patients?","volume":"83","author":"Edan","year":"2023","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.humimm.2026.111763_b0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5493\/wjem.v4.i3.27","article-title":"Multiple sclerosis and the role of immune cells","volume":"4","author":"Hoglund","year":"2014","journal-title":"World J Exp Med"},{"issue":"6","key":"10.1016\/j.humimm.2026.111763_b0045","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.immuni.2017.06.012","article-title":"Protective and Pathological Immunity during Central nervous System Infections","volume":"46","author":"Klein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.humimm.2026.111763_b0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","article-title":"Role of the JAK\/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases","volume":"189","author":"Yan","year":"2018","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.humimm.2026.111763_b0055","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cytogfr.2013.03.005","article-title":"Suppression of cytokine signaling: the SOCS perspective","volume":"24","author":"Linossi","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1\u20132","key":"10.1016\/j.humimm.2026.111763_b0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jneuroim.2014.05.013","article-title":"Quantitative analysis of the suppressors of cytokine signaling 1 and 3 in peripheral blood leukocytes of patients with multiple sclerosis","volume":"273","author":"Sedeno-Monge","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010218","article-title":"Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis patients Treated with Interferon Beta or Glatiramer Acetate","volume":"21","author":"Rojas-Morales","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12026-011-8205-2","article-title":"Transcriptional regulation by STAT6","volume":"50","author":"Goenka","year":"2011","journal-title":"Immunol. Res."},{"key":"10.1016\/j.humimm.2026.111763_b0075","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.immunol.17.1.701","article-title":"The IL-4 receptor: signaling mechanisms and biologic functions","volume":"17","author":"Nelms","year":"1999","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.humimm.2026.111763_b0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.humimm.2026.111763_b0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/7651_2014_99","article-title":"Peripheral Blood Mononuclear Cells: Isolation, Freezing, Thawing, and Culture","volume":"1304","author":"Riedhammer","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13402-023-00853-2","article-title":"Single-cell transcriptomic profiling reveals immune cell heterogeneity in acute myeloid leukaemia peripheral blood mononuclear cells after chemotherapy","volume":"47","author":"Hu","year":"2024","journal-title":"Cell. Oncol. (Dordr.)"},{"issue":"13","key":"10.1016\/j.humimm.2026.111763_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137399","article-title":"Cytokine Profiling in Cerebrospinal Fluid of patients with newly Diagnosed Relapsing-Remitting Multiple Sclerosis (RRMS): Associations between Inflammatory Biomarkers and disease activity","volume":"25","author":"Gebka-Kepinska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.humimm.2026.111763_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17427","article-title":"Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate","volume":"9","author":"Barac","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.humimm.2026.111763_b0105","doi-asserted-by":"crossref","unstructured":"Alsheikh, M.M.E.-S., A,M., Gawish, H. H., & El-Desoky, E. T, Serum interleukin-23 level in rheumatoid arthritis patients: Relation to disease activity and severity. The Egyptian Rheumatologist, 2019. 41(2): p. 99-103.","DOI":"10.1016\/j.ejr.2018.07.001"},{"issue":"4","key":"10.1016\/j.humimm.2026.111763_b0110","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.humimm.2026.111763_b0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0120","first-page":"1","article-title":"SOCS proteins in development and disease","volume":"2","author":"Trengove","year":"2013","journal-title":"Am J Clin Exp Immunol"},{"key":"10.1016\/j.humimm.2026.111763_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712859","article-title":"Assessment of Expression of SOCS Genes in acquired Immune-Mediated Polyneuropathies","volume":"12","author":"Taheri","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2026.111763_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153418","article-title":"Suppressor of Cytokine Signaling-2 (SOCS2) Regulates the Microglial Response and Improves Functional Outcome after Traumatic Brain Injury in mice","volume":"11","author":"Basrai","year":"2016","journal-title":"PLoS One"},{"issue":"Pt 12","key":"10.1016\/j.humimm.2026.111763_b0135","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/brain\/awp289","article-title":"Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis","volume":"132","author":"Brucklacher-Waldert","year":"2009","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.humimm.2026.111763_b0140","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/eji.200939305","article-title":"IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo","volume":"39","author":"Gyulveszi","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2026.111763_b0145","first-page":"208","article-title":"Cytokines gene expression in newly diagnosed multiple sclerosis patients","volume":"14","author":"Hasheminia","year":"2015","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2026.111763_b0150","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/15321819.2019.1655649","article-title":"Elevated serum level of IL-4 in neuromyelitis optica and multiple sclerosis patients","volume":"40","author":"Tahani","year":"2019","journal-title":"J. Immunoassay Immunochem."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/glia.10050","article-title":"Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions","volume":"38","author":"Hulshof","year":"2002","journal-title":"Glia"},{"key":"10.1016\/j.humimm.2026.111763_b0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jns.2016.02.049","article-title":"Association of IL4 and IL4R polymorphisms with multiple sclerosis susceptibility in Caucasian population: a meta-analysis","volume":"363","author":"Zhang","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"40","key":"10.1016\/j.humimm.2026.111763_b0165","doi-asserted-by":"crossref","first-page":"10714","DOI":"10.1523\/JNEUROSCI.1922-07.2007","article-title":"CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells","volume":"27","author":"Ponomarev","year":"2007","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.humimm.2026.111763_b0170","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.4049\/jimmunol.179.9.5966","article-title":"Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia","volume":"179","author":"Qin","year":"2007","journal-title":"J. Immunol."},{"issue":"36","key":"10.1016\/j.humimm.2026.111763_b0175","doi-asserted-by":"crossref","first-page":"31830","DOI":"10.1074\/jbc.M501316200","article-title":"JAK\/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3","volume":"280","author":"Yadav","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.humimm.2026.111763_b0180","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1080\/21655979.2021.2017577","article-title":"miR-3648 promotes lung adenocarcinoma-genesis by inhibiting SOCS2 (suppressor of cytokine signaling 2)","volume":"13","author":"Tu","year":"2022","journal-title":"Bioengineered"},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-014-3071-y","article-title":"Genetic variation in the JAK\/STAT\/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin\/NSAIDs: the Breast Cancer Health Disparities Study","volume":"147","author":"Slattery","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087668","article-title":"IL-4 suppresses the responses to TLR7 and TLR9 stimulation and increases the permissiveness to retroviral infection of murine conventional dendritic cells","volume":"9","author":"Sriram","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.humimm.2026.111763_b0195","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.4049\/jimmunol.1201396","article-title":"Regulation of Foxp3+ inducible regulatory T cell stability by SOCS2","volume":"190","author":"Knosp","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2026.111763_b0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jns.2017.02.015","article-title":"SOCS gene family expression profile in the blood of multiple sclerosis patients","volume":"375","author":"Toghi","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13148-016-0253-y","article-title":"Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells","volume":"8","author":"Sanders","year":"2016","journal-title":"Clin. Epigenetics"},{"issue":"6","key":"10.1016\/j.humimm.2026.111763_b0210","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200022","article-title":"CLMP Promotes Leukocyte Migration across Brain Barriers in Multiple Sclerosis","volume":"9","author":"Fournier","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.humimm.2026.111763_b0215","article-title":"The effect of Peripheral Immune Cell Counts on the risk of Multiple Sclerosis: a Mendelian Randomization Study","volume":"13","author":"He","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2026.111763_b0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/imcb.12625","article-title":"In Semliki Forest virus encephalitis, suppressor of cytokine signaling 4 (SOCS4) is an essential modulator of immune responses that mediates the balance between immunopathology and virus clearance","volume":"101","author":"Kedzierski","year":"2023","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.humimm.2026.111763_b0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener Dis Manag"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885926001096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885926001096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:09:45Z","timestamp":1781280585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885926001096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0198885926001096"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2026.111763","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced socs2 expression and elevated IL-4\/IL-23 levels in multiple sclerosis patients: Implications for immune dysregulation","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2026.111763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111763"}}